Texas Tech University Health Sciences Center

Running trials

• Recruiting

  Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic

  NCT07807345· Phase 1· Sutro Biopharma, Inc.· Source

• Recruiting

  PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis

  NCT07611214· Phase 4· Aurinia Pharmaceuticals Inc.· Source

• Recruiting

  Snacks and Brain Health

  NCT07348406· Phase 1/2· Texas Tech University Health Sciences Center· Source

• Recruiting

  Ketamine for Pain, Opioid Use, and Mental Health in Orthopedic Trauma Patients

  NCT06903819· Phase 4· Texas Tech University Health Sciences Center· Source

• Recruiting

  OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

  NCT07136012· Phase 3· Amgen· Source

• Recruiting

  A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

  NCT06966700· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  CONtiNuous glucosE Monitoring (CGM) in People wiTh Type 2 Diabetes Not on Insulin

  NCT06601166· DexCom, Inc.· Source

• Recruiting

  Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

  NCT05879926· Phase 3· NRG Oncology· Source

• Recruiting

  Curcumin and Retinal Study

  NCT05774704· Phase 1/2· Texas Tech University Health Sciences Center· Source

• Active, not recruiting

  RADIANCE Continued Access Protocol

  NCT05017935· ReCor Medical, Inc.· Source

• Active, not recruiting

  LIFE-BTK Randomized Controlled Trial

  NCT04227899· Abbott Medical Devices· Source

• Active, not recruiting

  SELUTION SLR™ 014 In-stent Restenosis

  NCT04280029· M.A. Med Alliance S.A.· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

  NCT04191499· Phase 2/3· Hoffmann-La Roche· Source

• Active, not recruiting

  Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer

  NCT04094688· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer

  NCT03939481· SWOG Cancer Research Network· Source

• Active, not recruiting

  Tocotrienols for Obesity of Postmenopausal Women

  NCT03705845· Phase 1/2· Texas Tech University Health Sciences Center· Source

• Recruiting

  Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

  NCT03067181· Phase 3· Children's Oncology Group· Source

• Active, not recruiting

  Breast Cancer WEight Loss Study (BWEL Study)

  NCT02750826· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

  NCT02567435· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

  NCT02785952· Phase 3· SWOG Cancer Research Network· Source

• Active, not recruiting

  Efficacy of Linaclotide in Type II Diabetics With Chronic Constipation

  NCT03119584· Phase 4· Texas Tech University Health Sciences Center, El Paso· Source

• Active, not recruiting

  Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

  NCT02306161· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Persona Total Knee Arthroplasty Outcomes Study

  NCT02255383· Zimmer Biomet· Source

• Recruiting

  Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors

  NCT02013336· Phase 1· South Plains Oncology Consortium· Source

• Active, not recruiting

  Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma

  NCT01856192· Phase 2· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

  NCT00588770· Phase 3· National Cancer Institute (NCI)· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Bladder cancer1 recruiting
• Childhood cancers1 recruiting
• Colorectal cancer1 recruiting
• Coronary artery disease1 recruiting
• Endometrial cancer1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Head and neck cancer1 recruiting
• Lung cancer1 recruiting
• Lupus (SLE)1 recruiting
• Mild cognitive impairment1 recruiting
• Neuroblastoma1 recruiting
• Ovarian cancer1 recruiting
• Sarcoma1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Withdrawn

  Early Childhood Obesity Among Rural Residents of West Texas

  NCT06831097· Texas Tech University Health Sciences Center· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

  NCT05646862· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

  NCT05832151· Phase 2· CinDome Pharma, Inc.· Source

• Completed

  A Prospective Single-Arm Multicenter StuDy of the BarE TEmporary SPur StEnt System foR the tREatment of Vascular Lesions Located in the infrapoplitEal Arteries beLow the Knee (DEEPER REVEAL)

  NCT05358353· ReFlow Medical, Inc.· Source

• Withdrawn

  Prevention of Age-associated Cardiac and Vascular Dysfunction Using Avmacol ES

  NCT05408559· Phase 1/2· Texas Tech University Health Sciences Center· Source

• Completed

  A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes

  NCT04560998· Phase 3· Novo Nordisk A/S· Source

• Completed

  Tai Chi for Knee OA Pain Management: a Mechanistic Study

  NCT04046003· Texas Tech University Health Sciences Center· Source

• Completed

  Gastric Electrical Stimulation (GES) and Pyloroplasty for the Treatment of Gastroparesis

  NCT03123809· Texas Tech University Health Sciences Center, El Paso· Source

• Completed

  Benefit of Transradial Approach in Chronic Kidney Disease Population Undergoing Cardiac Catheterization

  NCT02933892· Phase 4· Texas Tech University Health Sciences Center· Source

• Completed

  A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A

  NCT02615691· Phase 3· Baxalta now part of Shire· Source

• Completed

  Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

  NCT02180867· Phase 2/3· National Cancer Institute (NCI)· Source

• Completed

  Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

  NCT00861705· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

  NCT00324805· Phase 3· National Cancer Institute (NCI)· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Multiple myeloma40 works · 0 trials
• Fatty liver disease (MASLD/MASH)35 works · 0 trials
• Deep vein thrombosis and pulmonary embolism27 works · 0 trials
• Hodgkin lymphoma16 works · 0 trials
• Aortic stenosis12 works · 0 trials
• Vitiligo11 works · 0 trials
• Diffuse large B-cell lymphoma10 works · 1 trial
• Hypothyroidism10 works · 0 trials
• Hidradenitis suppurativa10 works · 0 trials
• Gastroparesis6 works · 2 trials
• Diabetic neuropathy5 works · 0 trials
• Haemophagocytic lymphohistiocytosis5 works · 0 trials
• Trigeminal neuralgia3 works · 0 trials